Cargando…

A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection

Platelet-rich plasma (PRP) is the most innovative blood-derived product used in regenerative medicine. We aimed to investigate the therapeutic efficacy of PRP urethral sphincter injection for the management of postprostatectomy incontinence (PPI). In total, 28 PPI patients with a mean age of 71.8 ± ...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ping-Jui, Jiang, Yuan-Hong, Kuo, Hann-Chorng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940644/
https://www.ncbi.nlm.nih.gov/pubmed/33686126
http://dx.doi.org/10.1038/s41598-021-84923-1
_version_ 1783661983440044032
author Lee, Ping-Jui
Jiang, Yuan-Hong
Kuo, Hann-Chorng
author_facet Lee, Ping-Jui
Jiang, Yuan-Hong
Kuo, Hann-Chorng
author_sort Lee, Ping-Jui
collection PubMed
description Platelet-rich plasma (PRP) is the most innovative blood-derived product used in regenerative medicine. We aimed to investigate the therapeutic efficacy of PRP urethral sphincter injection for the management of postprostatectomy incontinence (PPI). In total, 28 PPI patients with a mean age of 71.8 ± 8.9 years were prospectively enrolled. They received four PRP urethral sphincter injections each month. The clinical outcomes were assessed 3 months after the fourth injection as posttreatment Global Response Assessment (GRA) score, the newly designed visual analogue scale of stress urinary incontinence (VAS of SUI), and in urodynamic parameters. After injections, the posttreatment median GRA with quartiles was 2.0 (1.0, 2.0). Overall, six (21.4%) patients achieved complete continence and pad-free status, 20 (71.4%) achieved successful outcome (GRA score ≥ 2), and 26 (92.9%) showed clinical improvement (GRA score ≥ 1). The VAS of SUI significantly improved from 6.5 (5.0, 8.0) to 3.5 (2.0–5.8) (p < 0.001) as well as abdominal leak point pressure, from 57.5 (50.0, 115.0) to 126.0 (68.3, 150.0), (p = 0.004). After repeated PRP urethral sphincter injections, the SUI severity reduced significantly with high success rates. There was no major adverse event, except three patients with mild hematuria and micturition pain. In conclusion, PRP urethral sphincter injection is safe and effective as a novel management of PPI.
format Online
Article
Text
id pubmed-7940644
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79406442021-03-10 A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection Lee, Ping-Jui Jiang, Yuan-Hong Kuo, Hann-Chorng Sci Rep Article Platelet-rich plasma (PRP) is the most innovative blood-derived product used in regenerative medicine. We aimed to investigate the therapeutic efficacy of PRP urethral sphincter injection for the management of postprostatectomy incontinence (PPI). In total, 28 PPI patients with a mean age of 71.8 ± 8.9 years were prospectively enrolled. They received four PRP urethral sphincter injections each month. The clinical outcomes were assessed 3 months after the fourth injection as posttreatment Global Response Assessment (GRA) score, the newly designed visual analogue scale of stress urinary incontinence (VAS of SUI), and in urodynamic parameters. After injections, the posttreatment median GRA with quartiles was 2.0 (1.0, 2.0). Overall, six (21.4%) patients achieved complete continence and pad-free status, 20 (71.4%) achieved successful outcome (GRA score ≥ 2), and 26 (92.9%) showed clinical improvement (GRA score ≥ 1). The VAS of SUI significantly improved from 6.5 (5.0, 8.0) to 3.5 (2.0–5.8) (p < 0.001) as well as abdominal leak point pressure, from 57.5 (50.0, 115.0) to 126.0 (68.3, 150.0), (p = 0.004). After repeated PRP urethral sphincter injections, the SUI severity reduced significantly with high success rates. There was no major adverse event, except three patients with mild hematuria and micturition pain. In conclusion, PRP urethral sphincter injection is safe and effective as a novel management of PPI. Nature Publishing Group UK 2021-03-08 /pmc/articles/PMC7940644/ /pubmed/33686126 http://dx.doi.org/10.1038/s41598-021-84923-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Lee, Ping-Jui
Jiang, Yuan-Hong
Kuo, Hann-Chorng
A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection
title A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection
title_full A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection
title_fullStr A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection
title_full_unstemmed A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection
title_short A novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection
title_sort novel management for postprostatectomy urinary incontinence: platelet-rich plasma urethral sphincter injection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940644/
https://www.ncbi.nlm.nih.gov/pubmed/33686126
http://dx.doi.org/10.1038/s41598-021-84923-1
work_keys_str_mv AT leepingjui anovelmanagementforpostprostatectomyurinaryincontinenceplateletrichplasmaurethralsphincterinjection
AT jiangyuanhong anovelmanagementforpostprostatectomyurinaryincontinenceplateletrichplasmaurethralsphincterinjection
AT kuohannchorng anovelmanagementforpostprostatectomyurinaryincontinenceplateletrichplasmaurethralsphincterinjection
AT leepingjui novelmanagementforpostprostatectomyurinaryincontinenceplateletrichplasmaurethralsphincterinjection
AT jiangyuanhong novelmanagementforpostprostatectomyurinaryincontinenceplateletrichplasmaurethralsphincterinjection
AT kuohannchorng novelmanagementforpostprostatectomyurinaryincontinenceplateletrichplasmaurethralsphincterinjection